Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

To assess the influence of graft-versus-host disease (GVHD) on the outcome of patients with advanced haematological malignancies (AEM) who received a primary, unmodified allogeneic peripheral blood progenitor cells transplant (allo-PBT) from a human leucocyte antigen (HLA) identical sibling donor, w e analysed 136 patients with myeloid neoplasms (n = 70) or lymphoproliferat ive disorders (n = 66), transplanted at 19 Spanish institutions. Median age was 35 years (range 1-61). The cumulative incidence of relapse for all pat ients was 34% (95% CI, 26-42%), 41% (95% CI, 33-49) for patients without GV HD and 14% (95% CI, 3-25) (P = 0.001) for patients with acute and chronic G VHD. After a median follow-up of 11 months (range 2-49), 60 (44%) patients remained alive with an actuarial probability of overall survival and diseas e-free survival (DFS) at 30 months of 31% (95% CL 21-41%) and 28% (95% CL 1 7-39%) respectively. In patients surviving >100 d, the low incidence of rel apse in those with acute and chronic GVHD led to a DFS of 57% (95% CI, 38-7 6%) compared with a DFS of 34% (95% CI, 17-51%) in the remaining patients ( P = 0.03). Our results indicate a reduced incidence of relapse for patients with AHM receiving an unmodified allo-PBT and developing acute and chronic GVHD, which results in an improved DFS.